Comparison · NCT03556761-e01ee689
Oral Furosemide vs Placebo Oral Tablet: Number of Subjects That Required for Additional Antihypertensives
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Oral Furosemide vs Placebo Oral Tablet: Number of Subjects That Required for Additional Antihypertensives. Trial comparisons, record NCT03556761-e01ee689. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03556761-e01ee689
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.13 | 0.0898 | 0.185 | wilson | |
| Risk in group 2 | 0.203 | 0.152 | 0.266 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0729 | -0.147 | 0.00193 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.641 | 0.404 | 1.02 | log | |
| Odds ratio, group 1 over group 2 | 0.587 | 0.34 | 1.02 | log | |
| Number needed to treat, for one fewer participant with the outcome on Oral Furosemide than on Placebo Oral Tablet | 13.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Oral Furosemide | Oral furosemide 20 mg/day for a total of 5 consecutive doses.~Oral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily | 25 | 192 | OG000 |
| Group 2 | Placebo Oral Tablet | Placebo once per day for a total of 5 consecutive doses.~Placebo Oral Tablet: Placebo, PO, daily | 39 | 192 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects That Required for Additional Antihypertensives
- Description
- Number of subjects that required additional hypertensive medication after discharge
- Time frame
- 0 to 6 weeks post-partum
- Population
Source ClinicalTrials.gov
Trial
- Title
- Furosemide for Accelerated Recovery of Blood Pressure Postpartum
- NCT number
- NCT03556761
- Phases
- PHASE2
- Conditions
- Hypertension, Pregnancy-Induced
- Interventions
- Oral furosemide, Placebo Oral Tablet
- Lead sponsor
- University of Pennsylvania
- Results first posted
- 2020-09-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03556761?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03556761-e01ee689